Factors influencing poor visual outcome in patients treated with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration

Clinical and Experimental Ophthalmology

Volumn 35, Issue 4, 2007, Pages 330-334

  Manku, Kiran K ^a,b   Rotchford, Alan ^a   Whitaker, John ^a   Amoaku, Winfried M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NONE   (Australia)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Photodynamic therapy; Verteporfin

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PREDICTION; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME;

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 34447638909     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01482.x     Document Type: Article

References (14)

1. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with Verteporfin: one-year results of two randomised clinical trials. TAP report. Arch Ophthalmol 1999; 117: 1239-45.
2. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with Verteporfin: two-year results of 2 randomised clinical trials. TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
3. TAP Study Group. Verteporfin therapy for subfoveal choroidal neovascularisation in age-related macular degeneration: Three-year results of open label extension of 2 randomized clinical trials -TAP reports No. 5. Arch Ophthalmol 2002; 120: 1307-15.
4. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: Two year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularisation - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
5. Arias L, Pujol O, Berniell J et al. Impact of lesion size on photodynamic therapy with Verteporfin of predominantly classic lesions in age-related macular degeneration. Br J Ophthalmol 2005; 89: 312-15.
6. Bressler N, Arnold J, Benchaboune M et al. Verteporfin therapy of subfoveal choroidal neovascularisation in patients with age-related macular degeneration: Additional information regarding baseline lesion composition. Arch Ophthalmol 2002; 120: 1443-55.
7. Blinder K, Bradley S, Bressler N et al. Effect of lesion size, visual acuity change with and without Verteporfin therapy for choroidal neovascularisation secondary to age-related macular degeneration: TAP and VIP report. Am J Ophthalmol 2003; 136: 407-18.
8. Barnes R, Gee L, Taylor S, Briggs M, Harding S. Outcomes in Verteporfin photodynamic therapy for choroidal neovascularisation -beyond the TAP study. Eye 2004; 18: 808-13.
9. TAP and VIP Study Groups. Photodynamic therapy of subfoveal choroidal neovascularisation with Verteporfin. Fluorescein angiographic guidelines for evaluation and treatment -TAP and VIP reports No. 2. Arch Ophthalmol 2003; 121: 1253-68.
10. Verteporfin Roundtable 2000 and 2001 participants, TAP and VIP Study Groups. Guidelines for using Verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularisation due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18.
11. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-9.
12. National Institute for Clinical Excellence. Final Appraisal Determination: Photodynamic Therapy for Age-related Macular Degeneration. Available from: http://www.nice.org.uk/Docref.asp?d=5410
13. Azab M, Benchaboune A, Blinder K etal. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: TAP and VIP Study report No. 4. Retina 2004; 24: 1-12.
14. Arnold J, Blinder K, Bressler N etal. Acute severe visual acuity decrease after photodynamic therapy with Verteporfin: Case reports from randomized clinical trials -TAP and VIP report No. 3. TAP and VIP study groups. Am J Ophthalmol 2004; 137: 683-96.